L6Y Stock Overview

Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. More details

L6Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 37.1% per year over past 5 years

Does not have a meaningful market cap (€1M)

Negative shareholders equity

Shares are highly illiquid

+ 3 more risks

My Notes

Capture your thoughts, links and company narrative

Wellfully Limited Competitors

Biofrontera

XTRA:B8FK

€14.0m

SynBiotic

DUSE:SBX

€26.8m

TFF Pharmaceuticals

MUN:0K30

€9.7m

Cantourage Group

XTRA:HIGH

€63.0m

Price History & Performance

Summary of share price highs, lows and changes for Wellfully
Historical stock prices
Current Share Price	AU$0.0005
52 Week High	AU$0.016
52 Week Low	AU$0.0005
Beta	-0.91
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.95%

Recent updates

Shareholder Returns

	L6Y	DE Pharmaceuticals	DE Market
7D	0%	-0.3%	-0.3%
1Y	n/a	-17.0%	7.0%

Return vs Industry: Insufficient data to determine how L6Y performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how L6Y performed against the German Market.

Price Volatility

Is L6Y's price volatile compared to industry and market?
L6Y volatility
L6Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: L6Y has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine L6Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	n/a	Paul Peros	www.wellfully.net

Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations.

Wellfully Limited Fundamentals Summary

How do Wellfully's earnings and revenue compare to its market cap?
L6Y fundamental statistics
Market cap	€886.36k
Earnings (TTM)	-€4.68m
Revenue (TTM)	€997.10k

0.9x

P/S Ratio

-0.2x

P/E Ratio

Is L6Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
L6Y income statement (TTM)
Revenue	AU$1.66m
Cost of Revenue	AU$1.86m
Gross Profit	-AU$200.41k
Other Expenses	AU$7.60m
Earnings	-AU$7.80m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.016
Gross Margin	-12.05%
Net Profit Margin	-469.00%
Debt/Equity Ratio	-98.7%

How did L6Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/10/25 16:42
End of Day Share Price	2023/07/28 00:00
Earnings	2022/12/31
Annual Earnings	2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wellfully Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Wellfully DB:L6Y Stock Report